A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD

NCT02986321 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1130

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: CHF6001
DRUG: Budesonide
DRUG: Placebo

Sponsor

Chiesi Farmaceutici S.p.A.